Who are Pyrazapon's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Suprane, Metabarbital, Trichlophos, Paxipam, Klonopin, Anestan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ripazepam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pyrazapon — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pyrazapon (RIPAZEPAM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ripazepam. Area: Neuroscience.

phase 2 ripazepam GABA-A receptor; anion channel Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Pyrazapon (RIPAZEPAM). Ripazepam is thought to work by modulating the activity of GABA receptors in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pyrazapon TARGET	RIPAZEPAM		phase 2	ripazepam	GABA-A receptor; anion channel
Suprane	DESFLURANE	Baxter	marketed	General Anesthetic [EPC]	GABA-A receptor; anion channel	1992-01-01
Metabarbital	METHARBITAL	AbbVie	marketed	metharbital	GABA-A receptor; anion channel	1982-01-01
Trichlophos	TRICLOFOS	Sanofi	marketed	triclofos	GABA-A receptor; anion channel	1982-01-01
Paxipam	HALAZEPAM	Merck & Co.	marketed	halazepam	GABA-A receptor; anion channel	1981-01-01
Klonopin	clonazepam	Generic (originally Roche)	marketed	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel	1975-06-04
Anestan	HALOTHANE		marketed	halothane	GABA-A receptor; anion channel	1958-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ripazepam class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pyrazapon — Competitive Intelligence Brief. https://druglandscape.com/ci/ripazepam. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing